Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between Low Malignant Potential (LMP) and malignant ovarian tumours

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2753-2758

  Määttä, Milla ^a   Talvensaari Mattila, Anne ^a   Turpeenniemi Hujanen, Taina ^a   Santala, Markku ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Low malignant potential ovarian tumour; MMP 2; MMP 2 TIMP 2; Ovarian carcinoma; TIMP 1; TIMP 2

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 34547739709     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Trope C and Kaern J: Management of borderline tumours of the ovary: state of the art. Semin Oncol 25: 372-380, 1998.
2. Eisenkop SM, Spirtos NM, Montag TW, Nalick RH and Wang HJ: The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 47: 203-209, 1992.
3. Santala M, Risteli J, Risteli L, Puistola U, Kacinski BM, Stanley ER and Kauppila A: Synthesis and breakdown of fibrillar collagens; concomitant phenomena in ovarian cancer. Br J Cancer 77: 1825-1831, 1998.
4. Santala M, Simojoki M, Risteli J, Risteli L and Kauppila A: Type I and type III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer. Clin Cancer Res 5: 4091-4096, 1999.
5. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biological activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
6. Gomez DE, Alonso DF, Yoshiji H and Thorgeirsson UP: Tissue inhibitors of metalloproteinases: structure, regulation and biological function. Eur J Cell Biol 74: 111-122, 1997.
7. Maatta M, Santala M, Soini Y, Talvensaari-Mattila A and Turpeenniemi-Hujanen T: Matrix metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in low malignant potential ovarian tumours. Tumor Biol 25: 188-192, 2004.
8. Ylisirnio S, Hoyhtya M and Turpenniemi-Hujanen T: Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer - TIMP as a prognostic marker. Anticancer Res 20: 1311-1316, 2000.
9. Fujimoto N, Mouri N, Iwata K, Ohuchi E, Okada Y and Hoyakawa T: A one-step sandwich enzyme immunoassay for human matrix metalloproteinase-2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin Chim Acta 221: 91-103, 1993.
10. Turpeenniemi-Hujanen T: Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87: 287-297, 2005.
11. Hoikkala S, Pääkkö P, Soini Y, Makitaro R, Kinnula V and Turpeenniemi-Hujanen T: Tissue MMP-2/TIMP-2-complex are better prognostic factors than serum MMP-2, MMP-9 or TIMP-1 in stage I-III lung carcinoma. Cancer Lett 236: 125-132, 2006.
12. Talvensaari-Mattila A, Santala M, Soini Y and Turpeenniemi-Hujanen T: Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res 25: 4101-4105, 2005.
13. Rauvala M, Puistola U and Turpeenniemi-Hujanen T: Gelatinases and their inhibitors in ovarian tumours; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 99: 656-663, 2005.
14. Reunanen N and Kähäri VM: Matrix metalloproteinase in cancer cell invasion. In: Cell Invasion. Heino J and Kähäri VM (eds.). Georgetown, Eurekah.com/Landes Bioscience, pp. 1-19, 2002.
15. Wurtz SO, Schrol AS, Sorensen NM, Lademann U, Christensen IJ, Mouridsen H and Brunner N: Tissue inhibitor of metalloproteinase-1 in breast cancer. Endocr Relat Cancer 12: 215-227, 2005.
16. De Nictolis M, Garbisa S, Lucarini G, Goteri G, Masiero L, Ciavatti A, Garzetti GG, Stetler-Stevenson WG, Fabris G, Biagini G and Prat J: 72-Kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors of the ovary: a clinicopathologic, immunohistochemical, and serological study. Int J Gynecol Pathol 15: 102-109, 1996.
17. Miyagi E, Yasumitsu H, Hirahara F, Nagashima Y, Minaguchi H, Miyazaki K and Umeda M: Marked induction of gelatinases, especially type B, in host fibroblasts by human ovarian cancer cells in athymic mice. Clin Exp Metastasis 13: 89-96, 1995.
18. Westerlund A, Hujanen E, Puistola U and Turpeenniemi-Hujanen T: Fibroblasts stimulate human ovarian cancer cell invasion and expression of 72-kDa gelatinase A (MMP-2). Gynaecol Oncol 67: 76-82, 1997.
19. Fishman DA, Bafetti LM, Banionis S, Kearns AS, Chilukuri K and Stack MS: Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 80: 1457-1463, 1997.
20. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, de Nictolis M, Garbisa S, Masiero L, Romani C and Graziella B: Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian cystadenocarcinomas: clinical and prognostic implications. Anticancer Res 15: 2799-2804, 1995.